Table of Contents: HIV Surveillance Statistics of Persons Diagnosed in Kalamazoo County

Front Matter

Acronyms and Definitions 1
Prevalence Estimate Calculations 1
Risk Transmission Categories 1

Section 1: Data on Prevalent Cases

Table 1. Demographic Information on Prevalent HIV Infection Cases 1
Table 2. Sex, Race, and Risk Among Prevalent HIV Infection Cases 2

Section 2: New Diagnoses, Deaths, and Prevalence

Table 3. New Diagnoses, Deaths, and Prevalence of HIV Infection, by Year 3
Figure 1. New Diagnoses, Deaths, and Prevalence of HIV Infection, by Year 4
Table 4. Comparison of HIV Infection Prevalence to Michigan 4

HIV/STD/VH/TB Epidemiology Section
Division of Communicable Disease
Bureau of Disease Control, Prevention and Epidemiology
Michigan Department of Community Health

Lansing - HIV Surveillance Office
201 Townsend St., 5th Floor
Lansing, MI 48913
517-335-8165

Detroit - HIV Surveillance Office
1151 Taylor St., Room 211B
Detroit, MI 48202
313-876-0353

**WEBSITE**  http://www.michigan.gov/hivstd **WEBSITE**
Prevalence Estimate Calculations

HIV prevalence estimates include all persons living in Kalamazoo County at diagnosis of HIV Infection (any stage) and incorporates an approximation of those not reported or not yet diagnosed. All estimates are rounded to the nearest ten, and the minimum estimate given is 10. Prevalence estimates were most recently revised in January 2011, so the estimates in this report may vary in comparison to reports published before the revi-

Risk Transmission Categories - Definitions

Blood Recipients
Hemophiliacs, blood transfusion recipients, and organ recipients who received blood products prior to 1985 & persons documented to have ever received an infected organ or unit of blood.

Heterosexual Contact (HC):

Heterosexual Contact w/ Female Risk (HCFR): Males whose female sexual partners are known to be HIV-infected or at high risk for HIV. These partners meet one of the following criteria: IDU, hemophiliac, HIV infected transfusion recipient, or other HIV infected person of unknown risk.

Heterosexual Contact w/ Male (HCM): Females who have had sex with a male regardless of what is known about the male’s HIV status or behaviors.

Injection Drug Users (IDU)
Persons who have a history of injection drug use.

Men who have sex with men (MSM)
Males who have a history of sexual contact with other men.

MSM/IDU
MSM who also have a history of injection drug use.

Perinatal
HIV transmission from mother to child during birth or through breastfeeding.

Undetermined
Males and females with no identified risk.

Please note:
-Males whose only documented risk is sex with a female, and their female partner’s risk and HIV status is unknown fall into the undetermined risk category.
## TABLE 1. Demographic Information on Prevalent HIV Infection Cases Living in KALAMAZOO CO. at Diagnosis

### REPORTED PREVALENCE

<table>
<thead>
<tr>
<th>Race/Ethnicity</th>
<th>HIV Infection Non-Stage 3</th>
<th>HIV Infection Stage 3 (AIDS)</th>
<th>Total</th>
<th>Rate per 100,000‡§</th>
<th>Census 2010</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Num</td>
<td>Percent</td>
<td>Num</td>
<td>Percent</td>
<td>Num</td>
</tr>
<tr>
<td>White</td>
<td>220</td>
<td>78%</td>
<td>84</td>
<td>57%</td>
<td>162</td>
</tr>
<tr>
<td>Black</td>
<td>170</td>
<td>66%</td>
<td>58</td>
<td>39%</td>
<td>124</td>
</tr>
<tr>
<td>Hispanic</td>
<td>10</td>
<td>&lt;5%</td>
<td>5</td>
<td>3%</td>
<td>9</td>
</tr>
<tr>
<td>Asian/PI</td>
<td>10</td>
<td>&lt;5%</td>
<td>0</td>
<td>0%</td>
<td>&lt;5</td>
</tr>
<tr>
<td>American/AN</td>
<td>0</td>
<td>0%</td>
<td>0</td>
<td>0%</td>
<td>0</td>
</tr>
<tr>
<td>Multi/Other/Unk</td>
<td>10</td>
<td>&lt;5%</td>
<td>&lt;5</td>
<td>**</td>
<td>&lt;5</td>
</tr>
</tbody>
</table>

### SEX & RACE

<table>
<thead>
<tr>
<th>Sex</th>
<th>HIV Infection Non-Stage 3</th>
<th>HIV Infection Stage 3 (AIDS)</th>
<th>Total</th>
<th>Rate per 100,000‡§</th>
<th>Census 2010</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Num</td>
<td>Percent</td>
<td>Num</td>
<td>Percent</td>
<td>Num</td>
</tr>
<tr>
<td>Male</td>
<td>320</td>
<td>115%</td>
<td>123</td>
<td>83%</td>
<td>238</td>
</tr>
<tr>
<td>White Male</td>
<td>190</td>
<td>65%</td>
<td>74</td>
<td>50%</td>
<td>139</td>
</tr>
<tr>
<td>Black Male</td>
<td>120</td>
<td>45%</td>
<td>44</td>
<td>30%</td>
<td>89</td>
</tr>
<tr>
<td>Hispanic Male</td>
<td>10</td>
<td>&lt;5%</td>
<td>5</td>
<td>3%</td>
<td>8</td>
</tr>
<tr>
<td>Other Male</td>
<td>10</td>
<td>&lt;5%</td>
<td>0</td>
<td>0%</td>
<td>&lt;5</td>
</tr>
<tr>
<td>Female</td>
<td>80</td>
<td>37%</td>
<td>25</td>
<td>17%</td>
<td>62</td>
</tr>
<tr>
<td>White Female</td>
<td>30</td>
<td>13%</td>
<td>10</td>
<td>7%</td>
<td>23</td>
</tr>
<tr>
<td>Black Female</td>
<td>50</td>
<td>21%</td>
<td>14</td>
<td>9%</td>
<td>35</td>
</tr>
<tr>
<td>Hispanic Female</td>
<td>10</td>
<td>&lt;5%</td>
<td>0</td>
<td>0%</td>
<td>&lt;5</td>
</tr>
<tr>
<td>Other Female</td>
<td>10</td>
<td>&lt;5%</td>
<td>&lt;5</td>
<td>**</td>
<td>&lt;5</td>
</tr>
</tbody>
</table>

### RISK

<table>
<thead>
<tr>
<th>Risk Category</th>
<th>HIV Infection Non-Stage 3</th>
<th>HIV Infection Stage 3 (AIDS)</th>
<th>Total</th>
<th>Rate per 100,000‡§</th>
<th>Census 2010</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Num</td>
<td>Percent</td>
<td>Num</td>
<td>Percent</td>
<td>Num</td>
</tr>
<tr>
<td>Male-Male Sex (MSM)</td>
<td>200</td>
<td>75%</td>
<td>75</td>
<td>51%</td>
<td>150</td>
</tr>
<tr>
<td>Injection Drug Use (IDU)</td>
<td>30</td>
<td>8%</td>
<td>16</td>
<td>11%</td>
<td>24</td>
</tr>
<tr>
<td>MSM/IDU</td>
<td>20</td>
<td>9%</td>
<td>5</td>
<td>3%</td>
<td>14</td>
</tr>
<tr>
<td>Blood Products</td>
<td>10</td>
<td>&lt;5%</td>
<td>&lt;5</td>
<td>&lt;5</td>
<td>&lt;5</td>
</tr>
<tr>
<td>Heterosexual Contact (HC)</td>
<td>50</td>
<td>26%</td>
<td>13</td>
<td>9%</td>
<td>39</td>
</tr>
<tr>
<td>HCFR (Males)</td>
<td>10</td>
<td>&lt;5%</td>
<td>&lt;5</td>
<td>&lt;5</td>
<td>&lt;5</td>
</tr>
<tr>
<td>HCM (Females)</td>
<td>40</td>
<td>22%</td>
<td>11</td>
<td>7%</td>
<td>33</td>
</tr>
<tr>
<td>Perinatal</td>
<td>10</td>
<td>&lt;5%</td>
<td>&lt;5</td>
<td>&lt;5</td>
<td>&lt;5</td>
</tr>
<tr>
<td>Undetermined</td>
<td>90</td>
<td>32%</td>
<td>36</td>
<td>24%</td>
<td>68</td>
</tr>
</tbody>
</table>

### AGE AT HIV DIAGNOSIS

<table>
<thead>
<tr>
<th>Age Group</th>
<th>HIV Infection Non-Stage 3</th>
<th>HIV Infection Stage 3 (AIDS)</th>
<th>Total</th>
<th>Rate per 100,000‡§</th>
<th>Census 2010</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Num</td>
<td>Percent</td>
<td>Num</td>
<td>Percent</td>
<td>Num</td>
</tr>
<tr>
<td>0 - 12 years</td>
<td>10</td>
<td>&lt;5%</td>
<td>&lt;5</td>
<td>**</td>
<td>&lt;5</td>
</tr>
<tr>
<td>13 - 19 years</td>
<td>30</td>
<td>14%</td>
<td>7</td>
<td>5%</td>
<td>21</td>
</tr>
<tr>
<td>20 - 24 years</td>
<td>50</td>
<td>23%</td>
<td>17</td>
<td>11%</td>
<td>40</td>
</tr>
<tr>
<td>25 - 29 years</td>
<td>80</td>
<td>31%</td>
<td>29</td>
<td>20%</td>
<td>60</td>
</tr>
<tr>
<td>30 - 39 years</td>
<td>130</td>
<td>54%</td>
<td>43</td>
<td>29%</td>
<td>97</td>
</tr>
<tr>
<td>40 - 49 years</td>
<td>80</td>
<td>22%</td>
<td>35</td>
<td>24%</td>
<td>57</td>
</tr>
<tr>
<td>50 - 59 years</td>
<td>20</td>
<td>6%</td>
<td>12</td>
<td>8%</td>
<td>18</td>
</tr>
<tr>
<td>60 years and over</td>
<td>10</td>
<td>0%</td>
<td>&lt;5</td>
<td>**</td>
<td>&lt;5</td>
</tr>
<tr>
<td>Unspecified</td>
<td>0</td>
<td>0%</td>
<td>0</td>
<td>0%</td>
<td>0</td>
</tr>
</tbody>
</table>

### TOTAL

<table>
<thead>
<tr>
<th>Total</th>
<th>HIV Infection Non-Stage 3</th>
<th>HIV Infection Stage 3 (AIDS)</th>
<th>Total</th>
<th>Rate per 100,000‡§</th>
<th>Census 2010</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Num</td>
<td>Percent</td>
<td>Num</td>
<td>Percent</td>
<td>Num</td>
</tr>
<tr>
<td>400</td>
<td>152</td>
<td>100%</td>
<td>148</td>
<td>100%</td>
<td>300</td>
</tr>
</tbody>
</table>

*See front matter page i for descriptions of prevalence estimate calculations and risk category groupings. Risk categories used in Michigan are redefined as of January 2012. NOTE: Heterosexual contact for males includes only males whose sexual partners are known to be HIV infected or at high risk for HIV (HCFR). Heterosexual contact for females includes all females who have had sex with a male regardless of what is known about the male’s HIV status or behaviors (HCM).

1 Includes reports that contain patient name or are otherwise unduplicated. <5 and *** = 1, 2, 3, or 4 cases.
2 To calculate “1 out x” statements, divide the census number by total reported prevalence. For example, for non-Hispanic whites: 200,047 / 162 = 1,235. Thus, 1 out of every 1,235 non-Hispanic white persons in KALAMAZOO CO. are living with HIV. Rates and “1 out of x” statements are not reliable for <10 cases. Thus, rates for <10 cases are shown as “---”.
3 Rates are not reported for risk categories and age at diagnosis because no reliable denominator data exist for these groups.
4 In this report, persons described as white, black, Asian/Pacific Islander (PI), or American Indian/Alaska Native (AN) are all non-Hispanic; persons described as Hispanic might be of any race.
# TABLE 2. Sex, Race, and Risk Among Prevalent HIV Infection Cases Living in KALAMAZOO CO. at Diagnosis

## MALE

<table>
<thead>
<tr>
<th></th>
<th>White</th>
<th></th>
<th>Black</th>
<th></th>
<th>Hispanic</th>
<th></th>
<th>Other or Unknown</th>
<th></th>
<th>All Male</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Num</td>
<td>Percent</td>
<td>Num</td>
<td>Percent</td>
<td>Num</td>
<td>Percent</td>
<td>Num</td>
<td>Percent</td>
<td>Num</td>
<td>Percent</td>
</tr>
<tr>
<td>Male-Male sex</td>
<td>98</td>
<td>71%</td>
<td>45</td>
<td>51%</td>
<td>5</td>
<td>63%</td>
<td>&lt;5</td>
<td>**</td>
<td>150</td>
<td>63%</td>
</tr>
<tr>
<td>Injection Drug Use</td>
<td>6</td>
<td>4%</td>
<td>7</td>
<td>8%</td>
<td>0</td>
<td>0%</td>
<td>0</td>
<td>0%</td>
<td>13</td>
<td>5%</td>
</tr>
<tr>
<td>MSM/IDU</td>
<td>8</td>
<td>6%</td>
<td>6</td>
<td>7%</td>
<td>0</td>
<td>0%</td>
<td>0</td>
<td>0%</td>
<td>14</td>
<td>6%</td>
</tr>
<tr>
<td>Blood Products</td>
<td>&lt;5</td>
<td>**</td>
<td>&lt;5</td>
<td>**</td>
<td>0</td>
<td>0%</td>
<td>0</td>
<td>0%</td>
<td>&lt;5</td>
<td>**</td>
</tr>
<tr>
<td>Heterosexual Contact</td>
<td>&lt;5</td>
<td>**</td>
<td>5</td>
<td>6%</td>
<td>0</td>
<td>0%</td>
<td>0</td>
<td>0%</td>
<td>6</td>
<td>3%</td>
</tr>
<tr>
<td>Perinatal</td>
<td>0</td>
<td>0%</td>
<td>0</td>
<td>0%</td>
<td>0</td>
<td>0%</td>
<td>0</td>
<td>0%</td>
<td>0</td>
<td>0%</td>
</tr>
<tr>
<td>Undetermined</td>
<td>25</td>
<td>18%</td>
<td>24</td>
<td>27%</td>
<td>&lt;5</td>
<td>**</td>
<td>0</td>
<td>0%</td>
<td>52</td>
<td>22%</td>
</tr>
<tr>
<td><strong>Male Subtotal</strong></td>
<td>139</td>
<td>58%</td>
<td>89</td>
<td>37%</td>
<td>8</td>
<td>3%</td>
<td>&lt;5</td>
<td>**</td>
<td>238</td>
<td>100%</td>
</tr>
</tbody>
</table>

## FEMALE

<table>
<thead>
<tr>
<th></th>
<th>White</th>
<th></th>
<th>Black</th>
<th></th>
<th>Hispanic</th>
<th></th>
<th>Other or Unknown</th>
<th></th>
<th>All Female</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Num</td>
<td>Percent</td>
<td>Num</td>
<td>Percent</td>
<td>Num</td>
<td>Percent</td>
<td>Num</td>
<td>Percent</td>
<td>Num</td>
<td>Percent</td>
</tr>
<tr>
<td>Injection Drug Use</td>
<td>&lt;5</td>
<td>**</td>
<td>8</td>
<td>23%</td>
<td>0</td>
<td>0%</td>
<td>0</td>
<td>0%</td>
<td>11</td>
<td>18%</td>
</tr>
<tr>
<td>Blood Products</td>
<td>0</td>
<td>0%</td>
<td>0</td>
<td>0%</td>
<td>0</td>
<td>0%</td>
<td>0</td>
<td>0%</td>
<td>0</td>
<td>0%</td>
</tr>
<tr>
<td>Heterosexual Contact</td>
<td>13</td>
<td>57%</td>
<td>19</td>
<td>54%</td>
<td>&lt;5</td>
<td>**</td>
<td>0</td>
<td>0%</td>
<td>33</td>
<td>53%</td>
</tr>
<tr>
<td>Perinatal</td>
<td>&lt;5</td>
<td>**</td>
<td>0</td>
<td>0%</td>
<td>0</td>
<td>0%</td>
<td>&lt;5</td>
<td>**</td>
<td>&lt;5</td>
<td>**</td>
</tr>
<tr>
<td>Undetermined</td>
<td>6</td>
<td>26%</td>
<td>8</td>
<td>23%</td>
<td>0</td>
<td>0%</td>
<td>&lt;5</td>
<td>**</td>
<td>16</td>
<td>26%</td>
</tr>
<tr>
<td><strong>Female Subtotal</strong></td>
<td>23</td>
<td>37%</td>
<td>35</td>
<td>56%</td>
<td>&lt;5</td>
<td>**</td>
<td>&lt;5</td>
<td>**</td>
<td>62</td>
<td>100%</td>
</tr>
</tbody>
</table>

## ALL

<table>
<thead>
<tr>
<th></th>
<th>White</th>
<th></th>
<th>Black</th>
<th></th>
<th>Hispanic</th>
<th></th>
<th>Other or Unknown</th>
<th></th>
<th>Risk All</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Num</td>
<td>Percent</td>
<td>Num</td>
<td>Percent</td>
<td>Num</td>
<td>Percent</td>
<td>Num</td>
<td>Percent</td>
<td>Num</td>
</tr>
<tr>
<td>Male-Male sex</td>
<td>98</td>
<td>60%</td>
<td>45</td>
<td>36%</td>
<td>5</td>
<td>56%</td>
<td>&lt;5</td>
<td>**</td>
<td>150</td>
</tr>
<tr>
<td>Injection Drug Use</td>
<td>9</td>
<td>6%</td>
<td>15</td>
<td>12%</td>
<td>0</td>
<td>0%</td>
<td>0</td>
<td>0%</td>
<td>24</td>
</tr>
<tr>
<td>MSM/IDU</td>
<td>8</td>
<td>5%</td>
<td>6</td>
<td>5%</td>
<td>0</td>
<td>0%</td>
<td>0</td>
<td>0%</td>
<td>14</td>
</tr>
<tr>
<td>Blood Products</td>
<td>&lt;5</td>
<td>**</td>
<td>&lt;5</td>
<td>**</td>
<td>0</td>
<td>0%</td>
<td>0</td>
<td>0%</td>
<td>&lt;5</td>
</tr>
<tr>
<td>Heterosexual Contact</td>
<td>14</td>
<td>9%</td>
<td>24</td>
<td>19%</td>
<td>&lt;5</td>
<td>**</td>
<td>0</td>
<td>0%</td>
<td>39</td>
</tr>
<tr>
<td>Perinatal</td>
<td>&lt;5</td>
<td>**</td>
<td>0</td>
<td>0%</td>
<td>0</td>
<td>0%</td>
<td>&lt;5</td>
<td>**</td>
<td>&lt;5</td>
</tr>
<tr>
<td>Undetermined</td>
<td>31</td>
<td>19%</td>
<td>32</td>
<td>26%</td>
<td>&lt;5</td>
<td>**</td>
<td>&lt;5</td>
<td>**</td>
<td>68</td>
</tr>
</tbody>
</table>

## RACE ALL

<p>| | | | | | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Num</td>
<td>Percent</td>
<td>Num</td>
<td>Percent</td>
<td>Num</td>
<td>Percent</td>
<td>Num</td>
<td>Percent</td>
<td>Num</td>
</tr>
<tr>
<td>Male-Male sex</td>
<td>162</td>
<td>54%</td>
<td>124</td>
<td>41%</td>
<td>9</td>
<td>3%</td>
<td>5</td>
<td>2%</td>
<td>300</td>
</tr>
</tbody>
</table>
The prevalence of HIV in Michigan has steadily increased, since persons with HIV are living longer. This is largely due to improved anti-retroviral therapy.

The increase in HIV prevalence is also reflected in Figure 1 on page 5, which shows that the number of persons diagnosed, while stable for the last several years, is greater than the number of deaths each year. This directly contributes to the increase in prevalence. The current reported prevalence of HIV infection in KALAMAZOO CO. is 300. The prevalence of Stage 3 infection, which is a subset of the overall HIV infection prevalence, is 148.

As implied, the HIV infection section displays data on all persons with HIV, including those with Stage 3 infection, as well as those who have not progressed to Stage 3. Thus, persons represented in the Stage 3 section are also represented in the HIV infection section. The number of reported deaths includes deaths directly attributable to presence of HIV infection as well as deaths due to other causes.

NOTE: Reporting for recent years may not be complete. Data are not adjusted to account for reporting delays.

### TABLE 3. New Diagnoses, Deaths, and Prevalence of HIV Infection in KALAMAZOO CO., by Year

<table>
<thead>
<tr>
<th>Year</th>
<th>New HIV Diagnoses</th>
<th>Deaths</th>
<th>Prevalence</th>
<th>New Stage 3 Diagnoses</th>
<th>Deaths</th>
<th>Prevalence</th>
</tr>
</thead>
<tbody>
<tr>
<td>1983</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>1984</td>
<td>2</td>
<td>0</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>1985</td>
<td>8</td>
<td>2</td>
<td>9</td>
<td>3</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>1986</td>
<td>9</td>
<td>1</td>
<td>17</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>1987</td>
<td>16</td>
<td>4</td>
<td>29</td>
<td>7</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>1988</td>
<td>14</td>
<td>4</td>
<td>39</td>
<td>10</td>
<td>4</td>
<td>11</td>
</tr>
<tr>
<td>1989</td>
<td>23</td>
<td>4</td>
<td>58</td>
<td>7</td>
<td>4</td>
<td>14</td>
</tr>
<tr>
<td>1990</td>
<td>39</td>
<td>10</td>
<td>87</td>
<td>21</td>
<td>10</td>
<td>25</td>
</tr>
<tr>
<td>1991</td>
<td>24</td>
<td>8</td>
<td>103</td>
<td>10</td>
<td>8</td>
<td>27</td>
</tr>
<tr>
<td>1992</td>
<td>22</td>
<td>7</td>
<td>118</td>
<td>14</td>
<td>7</td>
<td>34</td>
</tr>
<tr>
<td>1993</td>
<td>20</td>
<td>13</td>
<td>125</td>
<td>25</td>
<td>12</td>
<td>47</td>
</tr>
<tr>
<td>1994</td>
<td>21</td>
<td>14</td>
<td>132</td>
<td>22</td>
<td>13</td>
<td>56</td>
</tr>
<tr>
<td>1995</td>
<td>21</td>
<td>14</td>
<td>139</td>
<td>28</td>
<td>13</td>
<td>71</td>
</tr>
<tr>
<td>1996</td>
<td>26</td>
<td>12</td>
<td>153</td>
<td>21</td>
<td>12</td>
<td>80</td>
</tr>
<tr>
<td>1997</td>
<td>17</td>
<td>15</td>
<td>155</td>
<td>22</td>
<td>13</td>
<td>89</td>
</tr>
<tr>
<td>1998</td>
<td>15</td>
<td>3</td>
<td>167</td>
<td>12</td>
<td>2</td>
<td>99</td>
</tr>
<tr>
<td>1999</td>
<td>16</td>
<td>5</td>
<td>178</td>
<td>5</td>
<td>5</td>
<td>99</td>
</tr>
<tr>
<td>2000</td>
<td>10</td>
<td>8</td>
<td>180</td>
<td>9</td>
<td>8</td>
<td>100</td>
</tr>
<tr>
<td>2001</td>
<td>12</td>
<td>5</td>
<td>187</td>
<td>6</td>
<td>5</td>
<td>101</td>
</tr>
<tr>
<td>2002</td>
<td>9</td>
<td>4</td>
<td>192</td>
<td>1</td>
<td>4</td>
<td>98</td>
</tr>
<tr>
<td>2003</td>
<td>13</td>
<td>8</td>
<td>197</td>
<td>5</td>
<td>6</td>
<td>97</td>
</tr>
<tr>
<td>2004</td>
<td>25</td>
<td>3</td>
<td>219</td>
<td>7</td>
<td>2</td>
<td>102</td>
</tr>
<tr>
<td>2005</td>
<td>18</td>
<td>5</td>
<td>232</td>
<td>14</td>
<td>3</td>
<td>113</td>
</tr>
<tr>
<td>2006</td>
<td>13</td>
<td>4</td>
<td>241</td>
<td>7</td>
<td>3</td>
<td>117</td>
</tr>
<tr>
<td>2007</td>
<td>10</td>
<td>8</td>
<td>243</td>
<td>9</td>
<td>6</td>
<td>120</td>
</tr>
<tr>
<td>2008</td>
<td>16</td>
<td>4</td>
<td>255</td>
<td>11</td>
<td>4</td>
<td>127</td>
</tr>
<tr>
<td>2009</td>
<td>23</td>
<td>6</td>
<td>272</td>
<td>9</td>
<td>5</td>
<td>131</td>
</tr>
<tr>
<td>2010</td>
<td>14</td>
<td>2</td>
<td>284</td>
<td>9</td>
<td>2</td>
<td>138</td>
</tr>
<tr>
<td>2011</td>
<td>16</td>
<td>0</td>
<td>300</td>
<td>10</td>
<td>0</td>
<td>148</td>
</tr>
<tr>
<td>TOTAL</td>
<td>473</td>
<td>173</td>
<td>306</td>
<td>158</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
FIGURE 1. New Diagnoses, Deaths, and Prevalence of HIV Infection in KALAMAZOO CO., by Year

TABLE 4. Comparison of HIV Infection Prevalence in KALAMAZOO CO. to State

<table>
<thead>
<tr>
<th>Residence at Diagnosis</th>
<th>Estimated Prevalence</th>
<th>HIV Infection Prevalence</th>
<th>Reported Prevalence</th>
<th>Cumulative Stage 3</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Non-Stage 3</td>
<td>Stage 3 (AIDS)</td>
<td></td>
</tr>
<tr>
<td>Kalamazoo Co.</td>
<td>400</td>
<td>152</td>
<td>148</td>
<td>300</td>
</tr>
<tr>
<td>Michigan Total</td>
<td>19,300</td>
<td>6,860</td>
<td>7,855</td>
<td>14,715</td>
</tr>
</tbody>
</table>